Home › Research › Caregiving
Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial
Perry NS, Bollen C, Perry EK, Ballard C.. Pharmacology, biochemistry, and behavior, 2003-06-01
Topic: Risk, prevention and care in population studies
Plain-language summary
S. lavandulaefolia Vahl. (Spanish sage) extracts and constituents have demonstrated anticholinesterase, antioxidant, anti-inflammatory, oestrogenic and CNS depressant (sedative) effects all of which are currently relevant to the treatment of Alzheimer's disease (AD). The essential oil inhibits the enzyme acetylcholinesterase (AChE) from human brain tissue and bovine erythrocyte and individual monoterpenoid constituents inhibit AChE with varying degrees of potency. In vivo AChE inhibition of select brain (striatal and hippocampal over cortical) AChE was obtained following oral administration of the essential oil to rats. In a study in healthy volunteers essential oil administration produced significant effects on cognition. In a pilot open-label study involving oral administration of the essential oil to patients with AD, a significant increase in diastolic and systolic blood pressure was observed in two patients, however this may have been due primarily to preexisting hypertension and there were no abnormalities in other vital signs or blood samples during the trial period. Although an open label trial is not free from practice effects or rater-caregiver expectations, statistically significant differences between baseline and 6 weeks treatment were a reduction in neuropsychiatric symptoms and an improvement in attention.
What this study adds
Evidence grade: Low
This is a trial. Spanish sage extracts and their components show several effects in the laboratory that are relevant to Alzheimer's disease, and a small open-label trial in patients found reduced neuropsychiatric symptoms and improved attention after 6 weeks. However, this was an open-label pilot study, so practice effects or rater and caregiver expectations cannot be ruled out, and it does not show whether the treatment changes the course of the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Perry, N. S., Bollen, C., Perry, E. K., & Ballard, C. (2003). Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacology, biochemistry, and behavior. https://doi.org/10.1016/s0091-3057(03)00108-4
Vancouver
Perry NS, Bollen C, Perry EK, Ballard C. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacology, biochemistry, and behavior. 2003. doi:10.1016/s0091-3057(03)00108-4. PMID: 12895683.
BibTeX
@article{perry2003-12895683,
author = {Perry, N. S. and Bollen, C. and Perry, E. K. and Ballard, C.},
title = {{Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial}},
journal = {Pharmacology, biochemistry, and behavior},
year = {2003},
doi = {10.1016/s0091-3057(03)00108-4},
pmid = {12895683},
url = {https://doi.org/10.1016/s0091-3057(03)00108-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- (Spanish sage) extracts and constituents have demonstrated anticholinesterase, antioxidant, anti-inflammatory, oestrogenic and CNS depressant (sedative) effects all of which are currently relevant to the treatment of Alzheimer's disease (AD).
- In a study in healthy volunteers essential oil administration produced significant effects on cognition.
- In a pilot open-label study involving oral administration of the essential oil to patients with AD, a significant increase in diastolic and systolic blood pressure was observed in two patients, however this may have been due primarily to preexisting hypertension and there were no abnormalities in other vital signs or blood samples during the trial period.
- Although an open label trial is not free from practice effects or rater-caregiver expectations, statistically significant differences between baseline and 6 weeks treatment were a reduction in neuropsychiatric symptoms and an improvement in attention.
Why it matters
Spanish sage extracts and their components show several effects in the laboratory that are relevant to Alzheimer's disease, and a small open-label trial in patients found reduced neuropsychiatric symptoms and improved attention after 6 weeks. However, this was an open-label pilot study, so practice effects or rater and caregiver expectations cannot be ruled out, and it does not show whether the treatment changes the course of the disease.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Study designopen-label trial
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Pharmacology, biochemistry, and behavior) |
| Journal's citation record | 2 / 4 | Pharmacology Biochemistry and Behavior: journal h-index 211 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “open-label trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 384 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.4 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 5 / 6 | Cited 23.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 19 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Clive G. Ballard: h-index 141 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University of Otago: institution h-index 665 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12895683) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Caregiving from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.